The predictive and prognostic value of serum CA125 kinetics and CA125 nadir during paclitaxel/platinum based chemotherapy (QT) in patients with advanced ovarian carcinoma (OC)

被引：0
|
作者：
Tibau, A. [1 ]
Ojeda, M. B. [1 ]
Nadal, R. M. [2 ]
Gallardo, A. [1 ]
Perez Altozano, J. [1 ]
Sala, N. [1 ]
Mazarico, J. M. [1 ]
Boguna, I. [1 ]
Artigas, V. [1 ]
Barnadas, A. [1 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp del Mar, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71548-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：457 / 457
页数：1
相关论文
共 50 条
  • [31] THE CLINICAL CORRELATES OF SERUM CA125 IN 169 PATIENTS WITH EPITHELIAL OVARIAN-CARCINOMA
    HAWKINS, RE
    ROBERTS, K
    WILTSHAW, E
    MUNDY, J
    MCCREADY, VR
    BRITISH JOURNAL OF CANCER, 1989, 60 (04) : 634 - 637
  • [32] Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125
    Nekulova, M
    Pecen, L
    Kalabova, R
    Simickova, M
    Topolcan, O
    Pikner, R
    Vondracek, V
    Valik, D
    CLINICAL CHEMISTRY, 2002, 48 (08) : 1364 - 1367
  • [33] Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
    Gupta, Divya
    Gunter, Marc J.
    Yang, Kathleen
    Lee, Stephen
    Zuckerwise, Lisa
    Chen, Lee-may
    Goldberg, Gary L.
    Huang, Gloria S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (03) : 529 - 534
  • [34] The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma
    Naveen S. Vasudev
    Ioannis Trigonis
    David A. Cairns
    Geoff D. Hall
    David P. Jackson
    Timothy Broadhead
    John Buxton
    Richard Hutson
    David Nugent
    Timothy J. Perren
    Archives of Gynecology and Obstetrics, 2011, 284 : 221 - 227
  • [35] The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma
    Vasudev, Naveen S.
    Trigonis, Ioannis
    Cairns, David A.
    Hall, Geoff D.
    Jackson, David P.
    Broadhead, Timothy
    Buxton, John
    Hutson, Richard
    Nugent, David
    Perren, Timothy J.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 284 (01) : 221 - 227
  • [36] MESOTHELIN EXPRESSION AND CA125 SERUM CONCENTRATION IN PATIENTS WITH OVARIAN CANCER
    Barczynski, B.
    Fraszczak, K.
    Tarkowski, R.
    Ziober-Malinowska, P.
    Kulak, K.
    Bobinski, M.
    Polak, G.
    Sobstyl, M.
    Bednarek, W.
    Kotarski, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 635 - 635
  • [37] USE OF CA125 TO PREDICT SURVIVAL OF PATIENTS WITH OVARIAN-CARCINOMA
    RUSTIN, GJS
    GENNINGS, JN
    NELSTROP, AE
    COVARRUBIAS, H
    LAMBERT, HE
    BAGSHAWE, KD
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 452 - 452
  • [38] CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy
    Richardson, Debra L.
    Seamon, Leigh G.
    Carlson, Matthew J.
    O'Malley, David M.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 233 - 236
  • [39] CA125 decline in patients with ovarian cancer treated with intravenous versus intraperitoneal platinum-based chemotherapy
    Richardson, D. L.
    Seamon, L. G.
    Carlson, M. J.
    O'Malley, D. M.
    Fowler, J. M.
    Copeland, L. J.
    Cohn, D. E.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S57 - S57
  • [40] Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125
    Abu Hassaan, Suher Othman
    DANISH MEDICAL JOURNAL, 2018, 65 (04):
12345